Amicus Therapeutics — Q2 2019 Earnings Presentation
24 slides from Amicus Therapeutics's earnings presentation, Aug 8, 2019
Slide 1: Forward-Looking Statements
Forward-Looking Statements General Corporate & Gene Therapy Overview This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting
Slide 2: 2Q19 and Early 3Q19 Highlights
2Q19 and Early 3Q19 Highlights Introduction 2Q19 Galafold Revenue of $44.1M - Continued Global Strength for Successful Rare Disease Launch AT-GAA PROPEL Pivotal Study Now Majority Enrolled Positive 2-Year Interim Clinical Results in CLN6 Batten Disease -Potential to Halt Progression of Fatal Neurolo
Slide 3: Galafold Global Launch
Galafold® (migalastat) Global Launch taking a leadership role in the treatment of Fabry disease “We push ideas as far and as fast as possible” - Amicus Belief Statement
Slide 4: Galafold Snapshot (as of June 30, 2019)
Galafold Snapshot (as of June 30, 2019) Galafold: Precision Medicine for Fabry Disease One of the Most Successful Rare Disease Launches 348 Amenable Variants in U.S. Label 9 Regulatory Approvals* : Argentina, Australia, Canada, EU, Israel, Japan, S. Korea, Switzerland , U.S. 24 Countries with Pricin
Slide 5: Galafold Global Launch Momentum
Galafold Global Launch Momentum (as of June 30, 2019) Galafold: Precision Medicine for Fabry Disease 2Q19 Strength Reflects Positive Momentum Across All Key Global Commercial Metrics Global: ~24% estimated global market share of treated amenable patients* with continued >90% compliance and adherence
Slide 6: Galafold Quarterly Performance
Galafold Quarterly Performance 2Q19 Revenue of $44.1M Grew 107% Year-over-Year Reflecting Continued Strong Growth in Global Adoption of First Fabry Oral Precision Medicine Galafold: Precision Medicine for Fabry Disease Consistent with Galafold adoption trends and ordering patterns in previous years,
Slide 7: Galafold Success and FY19 Revenue Guidance
Galafold Success and FY19 Galafold Revenue Guidance Galafold Sales in 2019 Represent the First Full Year of Launch in the Major Geographies in the World and will be between $160-$180M, with more than 1,000 Fabry Patients on Therapy by the End of 2019. Galafold Sales of $500M+ are Expected by 2023 Ga
Slide 8: Total Amenable Patient Population Estimate
2028 2018 Total Amenable Patient Population (“TAPP”) Estimate based on 35% - 50% amenability Fabry Disease is Increasingly Believed to be One of the Most Prevalent Human Genetic Diseases. The Total Amenable Patient Population (“TAPP”) has the Potential to Make Galafold a $1B+ Annual Product Galafold
Slide 9: AT-GAA Novel ERT for Pompe Disease
“We encourage and embrace constant innovation” - Amicus Belief Statement AT-GAA Novel ERT for Pompe Disease
Slide 10: PROPEL (ATB200-03) Study Design
PROPEL (ATB200-03) Study Design Participants with Late-Onset Pompe Disease ~100 Patients 90 WW Clinical Sites ERT-Switch ERT-Naïve AT-GAA is the First Ever Second-Generation Product for Any Lysosomal Disorder to Earn Breakthrough Therapy Designation (“BTD”) from the FDA AT-GAA for Pompe Disease Prel
Slide 11: PROPEL Study Global Enrollment
PROPEL (ATB200-03) Study Global Enrollment Sites in 29 Countries are Now Active to Ensure Broad Access and Experience with AT-GAA AT-GAA for Pompe Disease Phase 3 Enrollment Expected to Complete in 2019 with Data in 1H 2021 Targeting 90 Sites to Include all Leading Global Pompe Treatment Centers
Slide 12: AT-GAA: 2019 Objectives
AT-GAA: 2019 Objectives AT-GAA for Pompe Disease Advance AT-GAA for as Many Patients Worldwide as Quickly as Possible Additional Phase 1/2 Data (up to 24 Months) Breakthrough Therapy Designation Enroll PROPEL study (n=100) Present additional Phase 1/2 data at World Muscle Society (Oct. 1-5) Report n
Slide 13: Mepsevii for MPS VII: Exclusive Japanese Rights
Mepsevii™ for Mucopolysaccharidosis Type VII (MPS VII, Sly syndrome) Licensed Exclusive Japanese Rights to Mepsevii to Leverage Existing Infrastructure, Relationships and Experience In Clinical Development, Regulatory Approvals and Commercialization within the Lysosomal Disorders Community in Japan
Slide 14: Gene Therapy Pipeline
Gene Therapy Pipeline “We have a duty to obsolete our own technologies” - Amicus Belief Statement
Slide 15: Pipeline
Pipeline DISCOVERY PRECLINICAL PHASE 1/2 PHASE 3 REGULATORY COMMERCIAL Fabry Franchise Galafold®(migalastat) monotherapy Fabry Gene Therapy PENN Pompe Franchise AT-GAA (Novel ERT + Chaperone) Pompe Gene Therapy PENN Batten Franchise – Gene Therapies CLN6 Batten Disease NCH CLN3 Batten Disease NCH CL
Slide 16: Amicus-Penn Gene Therapy Collaboration
Amicus-Penn Gene Therapy Collaboration New Indications and Next Generation Research Program to Harness Combination of Amicus-Penn Technologies Amicus 2Q19 Results: Gene Therapy Pipeline Worldwide Rights to Penn’s Next Generation Gene Therapy Technologies for the Majority of Lysosomal Disorders 12 Ad
Slide 17: Key Takeaways for AAV-CLN6 Gene Therapy
5 Key Takeaways for AAV-CLN6 Gene Therapy Meaningful impact on motor and language function in children with a fatal neurologic disease that destroys brain function Evidence of disease stabilization in seven out of the eight children following AAV-CLN6 gene transfer Natural history cohort shows progr
Slide 18: Financial Summary
Financial Summary “We are business led and science driven” - Amicus Belief Statement
Slide 19: Financial Summary and Guidance
Financial Summary and Guidance Strong Balance Sheet with $575M+ Cash at 6/30/19 - Cash Runway into 2021 Financial Summary FINANCIAL POSITION Cash $575.7M Cash Runway1 Into 2021 Debt2 $152.8M CAPITALIZATION Shares Outstanding3 254,513,522 FINANCIAL GUIDANCE FY19 Galafold Revenue Guidance $160M-$180M
Slide 20: Summary & Milestones
Summary & Milestones “We are business led and science driven” - Amicus Belief Statement
Slide 21: 2019 Key Strategic Priorities
2019 Key Strategic Priorities Introduction 1 2 3 4 5 Nearly double annual revenue for Galafold® (guidance $160M-$180M) Complete enrollment in AT-GAA Pivotal Study (PROPEL) and report additional Phase 1/2 data Report additional 2-year clinical results in CLN6-Batten disease and complete enrollment in
Slide 22: Well-Positioned to Create Significant Value: Upcoming Milestones
Well-Positioned to Create Significant Value for Patients and Shareholders Upcoming Milestones Additional Phase 1/2 data (21 and 24 months) Breakthrough therapy designation (BTD) in LOPD Phase 1/2 study fully enrolled (Cohorts 1-4) PROPEL pivotal study enrollment (n=100) Additional Phase 1/2 data (Co
Slide 23: Thank You
Thank You “Our passion for making a difference unites us” -Amicus Belief Statement
Slide 24: Thank You
Thank You “Our passion for making a difference unites us” -Amicus Belief Statement Amicus